NCT04598269Phase 2Completed

Study of ATI-1777 in Adult Patients With Moderate or Severe Atopic Dermatitis

Study sponsor: Aclaris Therapeutics, Inc. · ACRS

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2021-04-08Actual

Enrollment · participants50Actual

Source updated2023-09-28Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Study details

Conditions studied

Atopic Dermatitis

Treatments or interventions studied

ATI-1777Drug
VehicleDrug

Primary outcomes · main study measures

Read the study measures

measure: Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 4; description: The EASI evaluation was performed by the Principal Investigator and evaluated atopic dermatitis in each of 3 body regions (trunk \[excluding groin and genitalia\], upper extremities \[excluding palms of hands\], and lower extremities \[excluding soles of feet\]). The EASI scoring system uses a defined process to grade the severity of the signs of atopic dermatitis and the extent affected. EASI Scores ranged from 0-72, with higher scores indicative of more severe disease.; timeFrame: Baseline, Week 4

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history